Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Licenses Resolver to University of Washington

NEW YORK, April 18 – Rosetta has licensed its Rosetta Resolver Gene Expression Data Analysis System to the University of Washington, the company said Wednesday.

University of Washington researchers will use the system, which analyzes gene expression, in efforts to study the pathogenesis of disease, the chemical contributions to behavior, and molecular influences on behavior.

"The Rosetta Resolver system offers high quality statistics and comprehensive analysis features to help us take our gene expression research to a higher level," Michael Katze, professor of microbiology at the University of Washington, said in a statement.

Resolver can be used with a variety of microarrays from different manufacturers, including Affymetrix GeneChips and Agilent DNA arrays. Rosetta released version 2.0 of the system last quarter and has granted Agilent Technologies sole distribution rights to it. 

Rosetta’s other licensees for the Resolver include the Harvard Center for Genomic Research, Immunex, Paradigm Genetics, and GlaxoSmithKline. Rosetta has also penned deals to use the technology in collaboration with Abbott Labs, Gemini Genomics, Monsanto, and Sangamo Biosciences.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.